<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02440178</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-micafungin</org_study_id>
    <nct_id>NCT02440178</nct_id>
  </id_info>
  <brief_title>Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia</brief_title>
  <official_title>Phase II Trial of Micafungin Prophylaxis During Induction Chemotherapy for Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether prophylaxis with micafungin is effective in
      the induction chemotherapy for newly diagnosed acute leukemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 19, 2015</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of proven/probable/possible invasive fungal infection</measure>
    <time_frame>the day of 6 weeks after induction chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>the day of 12 weeks after induction chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality</measure>
    <time_frame>the day of 12 weeks after induction chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>micafungin prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <arm_group_label>micafungin prophylaxis</arm_group_label>
    <other_name>mycamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A. patients belong to either A-1 or A-2 A-1. patients with newly diagnosed acute myeloid
        leukemia who approve to get induction chemotherapy with (cytarabine plus idarubicin) or
        (modified Fludarabine + cytarabine + idarubicin ) A-2. patients with newly diagnosed acute
        lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine +
        prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine +
        prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) +
        cyclophosphamide + vincristine + Adriamycin + dexamethasone) B. Eastern Cooperative
        Oncology Group performance status score is equal to or more than 2 C. patients who
        voluntarily sign the agreement

        Exclusion Criteria:

        A. evidence of proven/probable/possible fungal infection within 30 days before induction
        chemotherapy B. hypersensitivity to echinocandin C. patients had other malignancy within 5
        years D. previous treatment history with chemotherapy, radiation therapy, or
        immunosuppressive therapy.

        E. pregnant or breast-feeding women F. immunodeficient patients including AIDS G. patients
        with uncontrolled seizure or psychiatric disorder H. clinically significant heart disorder
        (myocardial infarction within 3 months or left ventricular ejection fraction &lt; 40%) I.
        interstitial lung disease J. previous organ transplantation history K. galactose
        intolerance L. patients who participated this study before.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youngil Koh, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>induction</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>antifungal</keyword>
  <keyword>micafungin</keyword>
  <keyword>phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

